Hytest North America is pleased to expand our HCV portfolio with Cat. # 8HC55, a new recombinant HCV core antigen.

For HCV antibody assay development, especially in indirect EIA formats, core antigen is an important target because of its strong immunoreactivity and broad genotype coverage, supporting sensitive and reliable anti-HCV detection. Commercial anti-HCV assays often use core together with non-structural antigens such as NS3 and NS4, while core remains a key component due to its strong seroreactivity and conserved sequence.

The new Cat. # 8HC55 antigen is:

• • Expressed in E. coli and features a C-terminal His10-tag with an additional cysteine residue.
• • ≥90% purity as determined by SDS-PAGE
• • Suitable for indirect and sandwich EIA formats
• • Providing reliable lot-to-lot consistency and robust performance for the development of sensitive and reliable anti-HCV assays

With the addition of Cat. # 8HC55, Hytest North America further expands its HCV antigen portfolio to support assay developers with high-quality recombinant raw materials:

• • 8HC51, recombinant HCV NS4 antigen expressed in E. coli, and contains C-terminal 10His-Cys-tag
• • 8HC52, recombinant HCV NS4 antigen expressed in a mammalian cell line, and contains N-terminal HAS-tag and C-terminal 10His-Cys-tag
• • 8HC53, recombinant NS3 antigen expressed in E. coli, and contains C-terminal 10His-Cys-tag
• • 8HC56, recombinant HCV core antigen expressed in a mammalian cell line, and contains N-terminal troponin C-tag and C-terminal 10His-Cys-tag

For more information, please visit our product page and related marketing materials.

You can find the Cat. # 8HC55 Datasheet on the product page.

For details, please contact Hytest North America.